Endocrinology

Ten Reasons Why Biosimilar Candidates Should Not Be Tested for Clinical Efficacy

October 31, 2020

Sarfaraz K. Niazi, PhD

Article

The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Biocon Reports Biosimilars Revenue Growth

October 23, 2020

Tony Hagen

Article

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.

Report: Specialty Drug Assessment Highlights Biosimilar Progress

October 12, 2020

Skylar Jeremias

Article

Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.

IQVIA: Biosimilars Could Save $100 Billion Over Next 5 Years

October 6, 2020

Skylar Jeremias

Article

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.

California's Governor Signs Bill for State to Produce Its Own Biosimilars, Insulins

September 29, 2020

Skylar Jeremias

Article

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

Stakeholders Joust Over Biosimilar Availability at PCOC20

September 25, 2020

Tony Hagen

Article

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Contributor: Drug Delivery Devices Help Originator Companies Retain Market Share

September 19, 2020

Isha Bangia, PharmD, MBA

Article

Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.

ACP Calls for Biologics Marketplace Reforms

September 16, 2020

Tony Hagen

Article

The American College of Physicians (ACP) said many reforms are needed to install appropriate checks and balances in the biologic drugs marketplace.

Rep Grothman Introduces Bill for Automatic Insulin Biosimilar Interchangeablity

September 15, 2020

Skylar Jeremias

Article

Representative Glenn Grothman, R-Wisconsin, says interchangeability for insulins makes sense based on the savings potential and safety record of these agents.

x